• Abreu MT 2002 The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr. Gastroenterol. Rep. 4: 481-489.

• Abreu MT, Yang H 2004 Is genetic testing in IBD ready for prime time? Am. J. Gastroenterol. 99: 316-318. *

• Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, Ellozy SH, Hegazi RAF, Yager J, Bodian C, Gorfine SR, Bauer JJ, Plevy SE, Sachar DB 2004 Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am. J. Gastroenterol. 99: 432-441. *

• Allenspach K, Luckschander N, Styner M, Seibold F, Doherr M, Aeschbach D, Gaschen F 2004 Evaluation of assays for perinuclear antineutrophilic cytoplasmic antibodies and antibodies to Saccharomyces cerevisiae in dogs with inflammatory bowel disease. Am. J. Vet. Res. 65: 1279-1283.

• Amarapurkar DN, Patel ND, Rane PS 2008 Diagnosis of Crohn's disease in India where tuberculosis is widely prevalent. World J. Gastroenterol. 14: 741-746. *

• Amre DK, Lu SE, Costea F, Seidman EG 2006 Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am. J. Gastroenterol. 101: 645-652. *

• Anand V, Russell AS, Tsuyuki R, Fedorak R 2008 Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can. J. Gastroenterol. 22: 33-36.

• Annese V, Andreoli A, Andriulli A, Dinca R, Gionchetti P, Latiano A, Lombardi G, Piepoli A, Poulain D, Sendid B, Colombel JF 2001 Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am. J. Gastroenterol. 96: 2407-2412. *

• Annese V, Lombardi G, Perri F, D'Inca R, Ardizzone S, Riegler G, Giaccari S, Vecchi M, Castiglione F, Gionchetti P, Cocchiara E, Vigneri S, Latiano A, Palmieri O, Andriulli A 2005 Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease - an IG-IBD study. Am. J. Gastroenterol. 100: 84-92. *

• Annese V, Piepoli A, Latiano A, Lombardi G, Napolitano G, Caruso N, Cocchiara E, Accadia L, Perri F, Andriulli A 2005 HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis. Colon Rectum 48: 57-64.

• Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF, Andriulli A 2004 Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Aliment Pharmacol. Ther. 20: 1143-1152. *

• Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J 2004 Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol. 99: 2376-2384. *

• Ashorn S, Honkanen T, Kolho KL, Ashorn M, Valineva T, Wei B, Braun J, Rantala I, Luukkaala T, Iltanen S 2008 Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm. Bowel Dis. Jul 10 [Epub ahead of print].

• Ashorn S, Raukola H, Valineva T, Ashorn M, Wei B, Braun J, Rantala I, Kaukinen K, Luukkaala T, Collin P, Mäki M, Iltanen S 2008 Elevated serum anti-Saccharomyces cerevisiae, anti-I2 and anti-OmpW antibody levels in patients with suspicion of celiac disease. J. Clin. Immunol. May 22 [Epub ahead of print]. *

• Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H 2008 Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 47: 142-144.

• Backer R, van Leeuwen F, Kraal G, den Haan JM 2008 CD8(-) dendritic cells preferentially cross-present Saccharomyces cerevisiae antigens. Eur. J. Immunol. 38: 370-380. *

• Barta Z, Csipo I, Antal-Szalmas P, Sipka S, Szabo G, Szegedi G 2001 Anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease. Orv. Hetil. 142: 2303-2307.

• Barta Z, Csipo I, Szabo GG, Szegedi G 2003 Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease. World J. Gastroenterol. 9: 2308-2312. *

• Bartunkova J, Kolarova I, Sediva A, Holzelova E 2002 Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases. Clin. Immunol. 102: 162-168. *

• Basu D, Lopez I, Kulkarni A, Sellin JH 2005 Impact of race and ethnicity on inflammatory bowel disease. Am. J. Gastroenterol. 100: 2254-2261. *

• Beaven SW, Abreu MT 2004 Biomarkers in inflammatory bowel disease. Curr. Opin. Gastroenterol. 20: 318-327.

• Benjamin J, Makharia GK, Joshi YK 2008 Association between intestinal permeability and anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease. Inflamm. Bowel Dis. May 1 [Epub ahead of print].

• Bergogne-Berezin E 2000 Treatment and prevention of antibiotic associated diarrhea. Int. J. Antimicrob. Agents 16: 521-526.

• Bickston SJ, Comerford LW, Cominelli F 2003 Future therapies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 518-523.

• Bitton A, Dobkin P, Edwardes MD, Sewitch M, Meddings J, Rawal S, Cohen A, Vermeire S, Dufresne L, Franchimont D, Wild GE 2008 Predicting relapse in Crohn's disease: a biopsychosocial model. Gut Apr 7 [Epub ahead of print].

• Bossuyt X 2006 Serologic markers in inflammatory bowel disease. Clin. Chem. 52: 171-181. *

• Bouhnik Y 2005 Diagnostic tools in inflammatory bowel diseases. Rev. Prat. 55: 977-983.

• Bouza E, Munoz P, Alonso R 2005 Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin. Microbiol. Infect. 11 Suppl. 4: 57-64.

• Brar HS, Surawicz CM 2000 Pseudomembranous colitis: an update. Can. J. Gastroenterol. 14: 51-56.

• Brem RB, Kruglyak L 2005 The landscape of genetic complexity across 5,700 gene expression traits in yeast. Proc. Natl. Acad. Sci. U.S.A. 102: 1572-1577. *

• Buckland MS, Mylonaki M, Rampton D, Longhurst HJ 2005 Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation. Clin. Diagn. Lab. Immunol. 12: 1328-1330. *

• Bueno de Mesquita M, Ferrante M, Henckaerts L, Joossens M, Janssens V, Hlavaty T, Pierik M, Joossens S, Van Schuerbeek N, Van Assche G, Rutgeerts P, Vermeire S, Hoffman I 2008 Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease. Eur. J. Pediatr. Aug 1 [Epub ahead of print]. *

• Buts JP, Dekeyser N, Stilmant C, Delem E, Smets F, Sokal E 2006 Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr. Res. 60: 24-29. *

• Canani RB, Romano MT, Greco L, Terrin G, Sferlazzas C, Barabino A, Fontana M, Roggero P, Guariso G, De Angelis G, Fecarotta S, Polito G, Cucchiara S 2004 Effects of disease activity on anti-Saccharomyces cerevisiae antibodies - Implications for diagnosis and follow-up of children with Crohn's disease. Inflamm. Bowel Dis. 10: 234-239. *

• Carson CF, Riley TV 2003 Non-antibiotic therapies for infectious diseases. Commun. Dis. Intell. 27 Suppl.: S143-S146.

• Castro-Santos P, Mozo L, Gutierrez C, Suarez A 2006 TNFalpha genotype influences development of IgA-ASCA antibodies in Crohn's disease patients with CARD15 wild type. Clin. Immunol. 121: 305-313. *

• Chutkan R 2004 Video capsule endoscopy in IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 54. May 7-8. *

• Cinemre H, Bilir C, Gokosmanoglu F, Kadakal F 2007 Anti-Saccharomyces cerevisiae antibodies in acute myocardial infarction. J. Investig. Med. 55: 444-449.

• Condino AA, Hoffenberg EJ, Accurso F, Penvari C, Anthony M, Gralla J, O'connor JA 2005 Frequency of ASCA seropositivity in children with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 41: 23-26. *

• Conrad K, Schmechta H, Klafki A, Lobeck G, Uhlig HH, Gerdi S, Henker J 2002 Serological differentiation of inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 14: 129-135.

• Cozar-Castellano I, Del Valle Machargo M, Trujillo E, Arteaga MF, Gonzalez T, Martin-Vasallo P, Avila J 2004 hIscA: a protein implicated in the biogenesis of iron-sulfur clusters. Biochim. Biophys. Acta 1700: 179-188. *

• Cruyssen BV, Peeters H, Hoffman IE, Laukens D, Coucke P, Marichal D, Cuvelier C, Remaut E, Veys EM, Mielants H, De Vos M, De Keyser F 2005 CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients. Clin. Exp. Immunol. 140: 354-359. *

• Culliford A, Markowitz D, Rotterdam H, Green PHR 2004 Scalloping of duodenal mucosa in Crohn's disease. Inflamm. Bowel Dis. 10: 270-273. *

• Czaja AJ 2004 Autoimmune liver disease. Curr. Opin. Gastroenterol. 20: 231-240.

• Czaja AJ, Norman GL 2003 Autoantibodies in the diagnosis and management of liver disease. J. Clin. Gastroenterol. 37: 315-329.

• Czaja AJ, Shums Z, Donaldson PT, Norman GL 2004 Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis. Dig. Dis. Sci. 49: 611-618. *

• Czerucka D, Piche T, Rampal P 2007 Review article: yeast as probiotics - Saccharomyces boulardii. Aliment. Pharmacol. Ther. 26: 767-778. *

• Damoiseaux JG, Bouten B, Linders AM, Austen J, Roozendaal C, Russel MG, Forget PP, Tervaert JW 2002 Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. J. Clin. Immunol. 22: 281-288. *

• Dassopoulos T 2001 Diagnostic methodologies: serology, endoscopy, and radiology. Curr. Gastroenterol. Rep. 3: 491-499.

• Dassopoulos T, Frangakis C, Cruz-Correa M, Talor MV, Burek CL, Datta L, Nouvet F, Bayless TM, Brant SR 2007 Antibodies to Saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm. Bowel Dis. 13: 143-151. *

• Davis MK, Andres JM, Jolley CD, Novak DA, Haafiz AB, Gonzalez-Peralta RP 2007 Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 45: 409-413.

• De Matos V, Russo PA, Cohen AB, Mamula P, Baldassano RN, Piccoli DA 2008 Frequency and clinical correlations of granulomas in children with Crohn disease. J. Pediatr. Gastroenterol. Nutr. 46: 392-398.

• Dendrinos KG, Becker JM, Stucchi AF, Saubermann LJ, Lamorte W, Farraye FA 2006 Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis. J. Gastrointest. Surg. 10: 1060-1064.

• Der G, Love T, Schreck J, Horn M 2005 Primary sclerosing cholangitis: a case presentation. Gastroenterol. Nurs. 28: 13-16. *

• Desai HG, Gupte PA 2005 Increasing incidence of Crohn's disease in India: is it related to improved sanitation? Indian J. Gastroenterol. 24: 23-24. *

• Desir B, Amre DK, Lu SE, Ohman-Strickland P, Dubinsky M, Fisher R, Seidman EG 2004 Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin. Gastroenterol. Hepatol. 2: 139-146. *

• Desplat-Jego S, Johanet C, Escande A, Goetz J, Fabien N, Olsson N, Ballot E, Sarles J, Baudon JJ, Grimaud JC, Veyrac M, Chamouard P, Humbel RL 2007 Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases … World J. Gastroenterol. 13: 2312-2318. *

• Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, Weishauss O, Spector L, Shtevi A, Altstock RT, Dotan N, Halpern Z 2006 Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 131: 366-378. *

• Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, Quiros A, Silber G, Wahbeh G, Katzir L, Vasiliauskas E, Bahar R, Otley A, Mack D, Evans J, Rosh J, Hemker MO, Leleiko N, Crandall W, Langton C, Landers C, Taylor KD, Targan SR, et al 2008 Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin. Gastroenterol. Hepatol. Jul 9 [Epub ahead of print].

• Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, et al 2006 Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am. J. Gastroenterol. 101: 360-367. *

• Elitsur Y, Lawrence Z, Tolaymat N 2005 The diagnostic accuracy of serologic markers in children with IBD: the West Virginia experience. J. Clin. Gastroenterol. 39: 670-673.

• Ernst R, Klemm R, Schmitt L, Kuchler K 2005 Yeast ATP-binding cassette transporters: cellular cleaning pumps. Methods Enzymol. 400: 460-484.

• Esters N, Pierik M, van Steen K, Vermeire S, Claessens G, Joossens S, Vlietinck R, Rutgeerts P 2004 Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am. J. Gastroenterol. 99: 299-305. *

• Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease 2002 Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am. J. Gastroenterol. 97: 1458-1462. *

• Fedorak RN, Madsen KL 2004 Probiotics and prebiotics in gastrointestinal disorders. Curr. Opin. Gastroenterol. 20: 146-155.

• Fedorak RN, Madsen KL 2004 Probiotics and the management of inflammatory bowel disease. Inflamm. Bowel Dis. 10: 286-299. *

• Fedorak RN, Penner R, Madsen KL 2006 Probiotics in the treatment of gastrointestinal diseases. US Gastroenterology Review, p. 28-31. *

• Fekih M, Ben Hlima S, Zitouni M, Matri S, Boubaker J, Makni S, Azza F 2007 Interest of serologic markers in inflammatory bowel disease. About 105 cases. Tunis. Med. 85: 821-828.

• Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman G, Altstock R, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S 2007 New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 56: 1394-1403.

• Forcione DG, Rosen MJ, Kisiel JB, Sands BE 2004 Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 53: 1117-1122. *

• Fresko I, Ugurlu S, Ozbakir F, Celik A, Yurdakul S, Hamuryudan V, Yazici H 2005 Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behcet's syndrome. Clin. Exp. Rheumatol. 23: S67-S70.

• Gao X, Hu PJ, He Y, Liao SY, Peng S, Chen MH 2005 Diagnostic role of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Zhonghua Nei Ke Za Zhi 44: 428-430.

• Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, Guerra Pinto A, Carolina Carneiro Aguirre A, Paiva Martins F, Marcos Andrade Goulart E, Sales Da Cunha A 2008 Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand. J. Gastroenterol. 43: 842-848. *

• Geboes K, De Hertogh G 2003 Indeterminate colitis. Inflamm. Bowel Dis. 9: 324-331. *

• Geddes K, Philpott DJ 2008 A new role for intestinal alkaline phosphatase in gut barrier maintenance. Gastroenterology 135: 8-12. *

• Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr 1995 Clostridium difficile-associated diarrhea and colitis. Infect. Control Hosp. Epidemiol. 16: 459-477.

• Ghadiminejad I, Baum H 1987 Evidence for the cell-surface localization of antigens cross-reacting with the "mitochondrial antibodies" of primary biliary cirrhosis. Hepatology 7: 743-749.

• Ghoshal UC, Ghoshal U, Singh H, Tiwari S 2007 Anti-Saccharomyces cerevisiae antibody is not useful to differentiate between Crohn's disease and intestinal tuberculosis in India. J. Postgrad. Med. 53: 166-170. *

• Gionchetti P, Rizzello F, Campieri M 2002 Probiotics in gastroenterology. Curr. Opin. Gastroenterol. 18: 235-239.

• Goldin BR, Gorbach SL 2008 Clinical indications for probiotics: an overview. Clin. Infect. Dis. 46 Suppl. 2: S96-S100.

• Granito A, Muratori L, Muratori P, Guidi M, Lenzi M, Bianchi FB, Volta U 2006 Anti-Saccharomyces cerevisiae antibodies (ASCA) in coeliac disease. Gut 55: 296. *

• Granito A, Zauli D, Muratori P, Muratori L, Grassi A, Bortolotti R, Petrolini N, Veronesi L, Gionchetti P, Bianchi FB, Volta U 2005 Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Aliment. Pharmacol. Ther. 21: 881-887. *

• Gupta A, Derbes C, Sellin J 2005 Clinical indications of the use of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in the evaluation of inflammatory bowel disease at an academic medical center. Inflamm. Bowel Dis. 11: 898-902. *

• Gupta N, Cohen SA, Bostrom AG, Kirschner BS, Baldassano RN, Winter HS, Ferry GD, Smith T, Abramson O, Gold BD, Heyman MB 2006 Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology 130: 1069-1077. *

• Gupta SK, Fitzgerald JF, Croffie JM, Pfefferkorn MD, Molleston JP, Corkins MR 2004 Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children. Inflamm. Bowel Dis. 10: 240-244. *

• Hadrich I, Vandewalle P, Cheikhrouhou F, Makni F, Krichen MS, Sendid B, Standaert-Vitse A, Ayadi A, Poulain D 2007 Ethnic and socio-cultural specificities in Tunisia have no impact on the prevalence of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients, their relatives or associated clinical factors. Scand. J. Gastroenterol. 42: 717-725. *

• Halfvarson J, Standaert-Vitse A, Jarnerot G, Sendid B, Jouault T, Bodin L, Duhamel A, Colombel JF, Tysk C, Poulain D 2005 ASCA in twins with inflammatory bowel disease. Gut 54: 1237-1243. *

• Halme L, Turunen U, Helio T, Paavola P, Walle T, Miettinen A, Jarvinen H, Kontula K, Farkkila M 2002 Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand. J. Gastroenterol. 37: 692-698. *

• Hanauer SB 2004 Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 26-31. *

• Harrer M, Reinisch W, Dejaco C, Kratzer V, Gmeiner M, Miehsler W, Norman GL, Gangl A, Vogelsang H 2003 Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur. J. Gastroenterol. Hepatol. 15: 1281-1285.

• Hartman C, Eliakim R, Shamir R 2004 Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies: serologic markers in inflammatory bowel disease. Isr. Med. Assoc. J. 6: 221-226.

• Holstein A, Burmeister J, Plaschke A, Rosemeier D, Widjaja A, Egberts EH 2006 Autoantibody profiles in microscopic colitis. J. Gastroenterol. Hepatol. 21: 1016-1020. *

• Hui T, Landers C, Vasiliauskas E, Abreu M, Dubinsky M, Papadakis KA, Price J, Lin YC, Huiying Y, Targan S, Fleshner P 2005 Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis. Colon Rectum 48: 1254-1262. *

• Iltanen S, Tervo L, Halttunen T, Wei B, Braun J, Rantala I, Honkanen T, Kronenberg M, Cheroutre H, Turovskaya O, Autio V, Ashorn M 2006 Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm. Bowel Dis. 12: 389-394. *

• Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, Shoenfeld Y 2005 Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 54: 1232-1236. *

• Jaskowski TD, Litwin CM, Hill HR 2006 Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin. Vaccine Immunol. 13: 655-660. *

• Jawhara S, Thuru X, Standaert-Vitse A, Jouault T, Mordon S, Sendid B, Desreumaux P, Poulain D 2008 Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J. Infect. Dis. 197: 972-980. *

• Johnson W Jr 2007 Final report on the safety assessment of Capsicum annuum extract, Capsicum annuum fruit extract, Capsicum annuum resin, Capsicum annuum fruit powder, Capsicum frutescens fruit, Capsicum frutescens fruit extract, Capsicum frutescens resin, and capsaicin. Int. J. Toxicol. 26 Suppl. 1: 3-106. *

• Joossens S, Colombel JF, Landers C, Poulain D, Geboes K, Bossuyt X, Targan S, Rutgeerts PJ, Reinisch W 2006 Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut 55: 1667-1669. *

• Joossens S, Pierik M, Rector A, Vermeire S, Ranst MV, Rutgeerts P, Bossuyt X 2006 Mannan binding lectin (MBL) gene polymorphisms are not associated with anti-Saccharomyces cerevisiae (ASCA) in patients with Crohn's disease. Gut 55: 746. *

• Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, Peeters M, Geboes K, Bossuyt X, Vandewalle P, Oberhuber G, Vogelsang H, Rutgeerts P, Colombel JF 2002 The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122: 1242-1247. *

• Joossens S, Suenaert P, Noman M, Vermeire S, Rutgeerts P 2005 Saccharomyces boulardii in Crohn's disease: effect on anti-Saccharomyces cerevisiae antibodies and intestinal permeability. Inflamm. Bowel Dis. 11: 863-864. *

• Kaila B, Orr K, Bernstein CN 2005 The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: accurate in identifying cases of Crohn's disease and predicting inflammatory disease. Can. J. Gastroenterol. 19: 717-721.

• Katz JA 2002 Advances in the medical therapy of inflammatory bowel disease. Curr. Opin. Gastroenterol. 18: 435-440.

• Khan K, Schwarzenberg SJ, Sharp H, Greenwood D, Weisdorf-Schindele S 2002 Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm. Bowel Dis. 8: 325-329. *

• Kilic ZM, Tunc B, Ayaz S, Filik L, Aktas S, Parlak E, Ulker A 2004 Antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies in inflammatory bowel diseases. Turk. J. Gastroenterol. 15: 238-242. *

• Kim BC, Park S, Han J, Kim JH, Kim TI, Kim WH 2007 Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course. Dig. Liver Dis. 39: 610-616.

• Kim BG, Kim YS, Kim JS, Jung HC, Song IS 2002 Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. Dis. Colon Rectum 45: 1062-1069.

• Kim JE, Kim KS, Seo JK 2003 Diagnostic role of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in pediatric inflammatory bowel disease. Korean J. Gastroenterol. 42: 297-302.

• Klebl FH, Bataille F, Bertea CR, Herfarth H, Hofstadter F, Scholmerich J, Rogler G 2003 Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm. Bowel Dis. 9: 302-307. *

• Klebl FH, Bataille F, Hofstadter F, Herfarth H, Scholmerich J, Rogler G 2004 Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease. Int. J. Colorectal Dis. 19: 319-324. *

• Konrad A, Rutten C, Flogerzi B, Styner M, Goke B, Seibold F 2004 Immune sensitization to yeast antigens in ASCA-positive patients with Crohn's disease. Inflamm. Bowel Dis. 10: 97-105. *

• Koutroubakis IE, Petinaki E, Mouzas IA, Vlachonikolis IG, Anagnostopoulou E, Castanas E, Maniatis AN, Kouroumalis EA 2001 Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am. J. Gastroenterol. 96: 449-454. *

• Krause I, Blank M, Cervera R, Font J, Matthias T, Pfeiffer S, Wies I, Fraser A, Shoenfeld Y 2007 Cross-reactive epitopes on beta2-glycoprotein-I and Saccharomyces cerevisiae in patients with the antiphospholipid syndrome. Ann. N. Y. Acad. Sci. 1108: 481-488.

• Krause I, Weinberger A 2008 Behcet's disease. Curr. Opin. Rheumatol. 20: 82-87.

• Kugathasan S 2001 Pediatric inflammatory bowel disease: clinical and therapeutic aspects. Curr. Opin. Gastroenterol. 17: 350-355.

• Kugathasan S, Werlin SL 1999 Measurement of pANCA (antineutrophil cytoplasmic antibodies) and ASCA (anti-saccharomyces cerevisiae) in screening for IBD in young children. Inflamm. Bowel Dis. 5: 283-284. *

• Lakatos PL, Altorjay I, Mandi Y, Lakatos L, Tumpek J, Kovacs A, Molnar T, Tulassay Z, Miheller P, Palatka K, Szamosi T, Fischer S, Papp J; the Hungarian IBD Study Group, Papp M 2008 Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins? Tissue Antigens 71: 552-559. *

• Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, Targan SR 2002 Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 123: 689-699. *

• Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD 2007 Ulcerative colitis: diagnosis and treatment. Am. Fam. Physician 76: 1323-1330. *

• Lawrance IC, Hall A, Leong R, Pearce C, Murray K 2005 A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm. Bowel Dis. 11: 890-897. *

• Lawrance IC, Murray K, Hall A, Sung JJ, Leong R 2004 A prospective comparative study of ASCA and pANCA in Chinese and caucasian IBD patients. Am. J. Gastroenterol. 99: 2186-2194. *

• Le Goff C, Chapelle JP, Lutteri L 2007 Comparison of five techniques to detect anti-Saccharomyces cerevisiae antibodies (ASCA) in serum for diagnosing Crohn's disease. Ann. Biol. Clin. (Paris) 65: 601-608.

• Lecis P, Germana B, Papa N, Bertiato G, Doglioni C, Galliani E, Biedo FC 2002 p-ANCA and ASCA antibodies in the differential diagnosis between ulcerative rectocolitis and Crohn's disease. Recenti Prog. Med. 93: 308-313.

• Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ 2008 The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig. Dis. Sci. Jul 10 [Epub ahead of print]. *

• Leong RW, Lawrance IC, Chow DK, To KF, Lau JY, Wu J, Leung WK, Chan FK, Sung JJ 2006 Association of intestinal granulomas with smoking, phenotype, and serology in Chinese patients with Crohn's disease. Am. J. Gastroenterol. 101: 1024-1029. *

• Li X, Conklin L, Alex P 2008 New serological biomarkers of inflammatory bowel disease. World J. Gastroenterol. 14: 5115-5124. *

• Lindberg E, Magnusson KE, Tysk C, Jarnerot G 1992 Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease. Gut 33: 909-913. *

• Linskens RK, Mallant-Hent RC, Groothuismink ZM, Bakker-Jonges LE, van de Merwe JP, Hooijkaas H, von Blomberg BM, Meuwissen SG 2002 Evaluation of serological markers to differentiate between ulcerative colitis and Crohn's disease: pANCA, ASCA and agglutinating antibodies to anaerobic coccoid rods. Eur. J. Gastroenterol. Hepatol. 14: 1013-1018.

• Linskens RK, Mallant-Hent RC, Murillo LS, von Blomberg BME, Alizadeh BZ, Pena AS 2004 Genetic and serological markers to identify phenotypic subgroups in a Dutch Crohn’s disease population. Dig. Liver Dis. 36: 29-34. *

• Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J 2003 Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype. Gut 52: 552-557. *

• Madsen KL 2001 The use of probiotics in gastrointestinal disease. Can. J. Gastroenterol. 15: 817-822.

• Mainardi E, Montanelli A, Dotti M, Villanacci V, Cestari R 2005 Anti-Saccharomyces cerevisiae antibodies in long-term consumers of anthranoid-containing laxatives. Inflamm. Bowel Dis. 11: 86-97. *

• Mainardi E, Villanacci V, Bassotti G, Liserre B, Rossi E, Incardona P, Falchetti D, Tonegatti L, Montanelli A, Barabino A, Coccia C, Gambini C 2007 Diagnostic value of serological assays in pediatric inflammatory bowel disorders. Digestion 75: 210-214.

• Makharia GK, Sachdev V, Gupta R, Lal S, Pandey RM 2007 Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig. Dis. Sci. 52: 33-39. *

• Malickova K, Lukas M, Donoval R, Sandova P, Janatkova I 2006 Novel anti-carbohydrate autoantibodies in patients with inflammatory bowel disease: are they useful for clinical practice? Clin. Lab. 52: 631-638.

• Mallant-Hent RC, Mary B, von Blomberg E, Yuksel Z, Wahab PJ, Gundy C, Meyer GA, Mulder CJ 2006 Disappearance of anti-Saccharomyces cerevisiae antibodies in coeliac disease during a gluten-free diet. Eur. J. Gastroenterol. Hepatol. 18: 75-78.

• Mallant-Hent RC, Mooij M, von Blomberg BM, Linskens RK, van Bodegraven AA, Savelkoul PH 2006 Correlation between Saccharomyces cerevisiae DNA in intestinal mucosal samples and anti-Saccharomyces cerevisiae antibodies in serum of patients with IBD. World J. Gastroenterol. 12: 292-297. *

• Marini NJ, Gin J, Ziegle J, Keho KH, Ginzinger D, Gilbert DA, Rine J 2008 The prevalence of folate-remedial MTHFR enzyme variants in humans. Proc. Natl. Acad. Sci. U.S.A. 105: 8055-8060. *

• Marteau P 2002 Inflammatory bowel disease. Endoscopy 34: 63-68.

• McFarland LV 2006 Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 101: 812-822. *

• McGovern DP, Taylor KD, Landers C, Derkowski C, Dutridge D, Dubinsky M, Ippoliti A, Vasiliauskas E, Mei L, Mengesha E, King L, Pressman S, Targan SR, Rotter JI 2008 MAGI2 genetic variation and inflammatory bowel disease. Inflamm. Bowel Dis. Aug 21 [Epub ahead of print]. *

• Melmed GY, Elashoff R, Chen GC, Nastaskin I, Papadakis KA, Vasiliauskas EA, Liu W, Landers C, Ippoliti AF, Targan SR 2007 Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin. Gastroenterol. Hepatol. 5: 602-608.

• Melmed GY, Fleshner PR, Bardakcioglu O, Ippoliti A, Vasiliauskas EA, Papadakis KA, Dubinsky M, Landers C, Rotter JI, Targan SR 2008 Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis. Colon Rectum 51: 100-108. *

• Mokrowiecka A, Gasiorowska A, Malecka-Panas E 2004 Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases. Pol. Merkuriusz. Lek. 17 Suppl. 1: 22-26.

• Mokrowiecka A, Gasiorowska A, Malecka-Panas E 2007 pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Hepatogastroenterology 54: 1443-1438.

• Montanelli A, Mainardi E, Vagni A, Villanacci V, Zambelli C, Cestari R, Cengia P, Minelli L, Missale G 2005 Immunological markers anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: a helpful diagnostic tool. Minerva Gastroenterol. Dietol. 51: 201-207.

• Moore MM, Fabricatorian D, Selby WS 2002 Assessment and relevance of enzyme-linked immunosorbent assay for antibodies to Saccharomyces cerevisiae in Australian patients with inflammatory bowel disease. Intern. Med. J. 32: 349-352.

• Moss AC, Cheifetz AS, Peppercorn MA 2006 Combined oral and topical mesalazine treatment for extensive ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 290-293. *

• Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang H, Targan SR 2004 Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126: 414-424. *

• Mpofu CM, Campbell BJ, Subramanian S, Marshall-Clarke S, Hart CA, Cross A, Roberts CL, McGoldrick A, Edwards SW, Rhodes JM 2007 Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's disease. Gastroenterology 133: 1487-1498. *

• Muller S, Schaffer T, Schoepfer AM, Hilty A, Bodmer T, Seibold F 2008 Partial overlap of anti-mycobacterial, and anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease. World J. Gastroenterol. 14: 3650-3661. *

• Muller S, Styner M, Seibold-Schmid B, Flogerzi B, Mahler M, Konrad A, Seibold F 2005 Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis. World J. Gastroenterol. 11: 6988-6994. *

• Muratori P, Muratori L, Guidi M, Maccariello S, Pappas G, Ferrari R, Gionchetti P, Campieri M, Bianchi FB 2003 Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin. Exp. Immunol. 132: 473-476. *

• Nakamura RM, Barry M 2001 Serologic markers in inflammatory bowel disease (IBD). MLO Med. Lab. Obs. 33: 8-15; quiz 16-19.

• Nakamura RM, Matsutani M, Barry M 2003 Advances in clinical laboratory tests for inflammatory bowel disease. Clin. Chim. Acta 335: 9-20. *

• Nakase H, Nishio A, Tamaki H, Matsuura M, Asada M, Chiba T, Okazaki K 2006 Specific antibodies against recombinant protein of insertion element 900 of Mycobacterium avium subspecies paratuberculosis in Japanese patients with Crohn's disease. Inflamm. Bowel Dis. 12: 62-69. *

• Odes S, Friger M, Vardi H, Claessens G, Bossuyt X, Riis L, Munkholm P, Wolters F, Yona H, Hoie O, Beltrami M, Tsianos E, Katsanos K, Mouzas I, Clofent J, Monteiro E, Messori A, Politi P, O'morain C, Limonard C, Russel M, Vatn M, Moum B, et al 2007 Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: a project of the European Collaborative Study Group on Inflammatory Bowel Disease. Inflamm. Bowel Dis. 13: 874-881. *

• Oshitani N 2004 Anti-Saccharomyces cerevisiae antibody and 5-aminosalicylic acid treatment. Am. J. Gastroenterol. 99: 955. *

• Oshitani N, Hato F, Kitagawa S, Maeda K, Higuchi K, Matsumoto T, Arakawa T 2003 Analysis of intestinal HLA-DR bound peptides and dysregulated immune responses to enteric flora in the pathogenesis of inflammatory bowel disease. Int. J. Mol. Med. 11: 99-104. *

• Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J; the Hungarian IBD Study Group, Lakatos PL 2008 New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am. J. Gastroenterol. 103: 665-681. *

• Papp M, Altorjay I, Lakatos P 2007 Relevance of serologic studies in inflammatory bowel diseases. Orv. Hetil. 148: 887-896.

• Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, Vitalis Z, Foldi I, Lakos G, Tumpek J, Udvardy ML, Harsfalvi J, Fischer S, Lakatos L, Kovacs A, Bene L, Molnar T, Tulassay Z, Miheller P, Veres G, Papp J, Lakatos PL 2007 Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm. Bowel Dis. 13: 984-992. *

• Papp M, Norman GL, Altorjay I, Lakatos PL 2007 Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J. Gastroenterol. 13: 2028-2036. *

• Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P 2001 Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am. J. Gastroenterol. 96: 730-734. *

• Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M 2007 IBD serological panels: facts and perspectives. Inflamm. Bowel Dis. 13: 1561-1566.

• Pham M, Lemberg DA, Day AS 2008 Probiotics: sorting the evidence from the myths. Med. J. Aust. 188: 304-308. *

• Pineton de Chambrun G, Colombel JF, Poulain D, Darfeuille-Michaud A 2008 Pathogenic agents in inflammatory bowel diseases. Curr. Opin. Gastroenterol. 24: 440-447. *

• Pinter M, Pinterova KM, Drahosova M, Rejchrt S, Douda T, Tacheci I, Kopacova M, Bures J 2007 Significance of serum antibodies ANCA, ASCA, ABBA in diagnostics of idiopathic intestinal inflammations. Cas. Lek. Cesk. 146: 863-867.

• Pochapin M 2000 The effect of probiotics on Clostridium difficile diarrhea. Am. J. Gastroenterol. 95: S11-S13.

• Preda CM, Diculescu M, Mirea V, Marica C, Vermeire S, Rutgeerts P, Oproiu A 2005 Significance of anti-Sacharomices cerevisiae antibodies (ASCA) in patients with inflammatory bowel diseases in Romania. Rom. J. Gastroenterol. 14: 23-26.

• Quinton JF, Sendid B, Reumaux D, Duthilleul P, Cortot A, Grandbastien B, Charrier G, Targan SR, Colombel JF, Poulain D 1998 Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 42: 788-791. *

• Ramanuja S, Wolf KM, Sadat MA, Mahoney SJ, Dinauer MC, Nelson RP Jr 2005 Newly diagnosed chronic granulomatous disease in a 53-year-old woman with Crohn disease. Ann. Allergy Asthma Immunol. 95: 204-209.

• Reddy KR, Colombel JF, Poulain D, Krawitt EL 2001 Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease. Am. J. Gastroenterol. 96: 252-253. *

• Reese GE, Constantinides VA, Simillis C, Darzi AW, Orchard TR, Fazio VW, Tekkis PP 2006 Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am. J. Gastroenterol. 101: 2410-2422. *

• Reinke CM, Messick CR 1994 Update on Clostridium difficile-induced colitis, Part 1. Am. J. Hosp. Pharm. 51: 1771-1781.

• Reumaux D, Sendid B, Poulain D, Duthilleul P, Dewit O, Colombel JF 2003 Serological markers in inflammatory bowel diseases. Best Pract. Res. Clin. Gastroenterol. 17: 19-35. *

• Riente L, Chimenti D, Pratesi F, Sedie AD, Tommasi S, Tommasi C, Bombardieri S, Migliorini P 2004 Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis. J. Rheumatol. 31: 920-924.

• Riis L, Vind I, Vermeire S, Wolters F, Katsanos K, Politi P, Freitas J, Mouzas IA, O'morain C, Ruiz-Ochoa V, Odes S, Binder V, Munkholm P, Moum B, Stockbrugger R, Langholz E 2007 The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm. Bowel Dis. 13: 24-32. *

• Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG 1998 Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 115: 822-829. *

• Saibeni S, Folli C, de Franchis R, Borsi G, Vecchi M 2003 Diagnostic role and clinical correlates of anti-Saccharomyces cerevisiae antibodies (ASCA) and anti-neutrophil cytoplasmic antibodies (p-ANCA) in Italian patients with inflammatory bowel diseases. Dig. Liver Dis. 35: 862-868.

• Sakly W, Jeddi M, Ghedira I 2007 Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis. Dig. Dis. Sci. 53: 1983-1987. *

• Sanchez JM, Maldonado JC, Torres EA, Rivera C 2005 Infliximab in Hispanics: characterization of response to infliximab in an ethnic minority with Crohn's disease. P. R. Health Sci. J. 24: 11-17.

• Sandborn WJ 2004 Serologic markers in inflammatory bowel disease: state of the art. Rev. Gastroenterol. Disord. 4: 167-174. *

• Sandborn WJ, Loftus EV Jr, Colombel JF, Fleming KA, Seibold F, Homburger HA, Sendid B, Chapman RW, Tremaine WJ, Kaul DK, Wallace J, Harmsen WS, Zinsmeister AR, Targan SR 2001 Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 7: 192-201. *

• Savage NW, Barnard K, Shirlaw PJ, Rahman D, Mistry M, Escudier MP, Sanderson JD, Challacombe SJ 2004 Serum and salivary IgA antibody responses to Saccharomyces cerevisiae, Candida albicans and Streptococcus mutans in orofacial granulomatosis and Crohn's disease. Clin. Exp. Immunol. 135: 483-489. *

• Schaffer T, Muller S, Flogerzi B, Seibold-Schmid B, Schoepfer AM, Seibold F 2007 Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans. Inflamm. Bowel Dis. 13: 1339-1346.

• Schoepfer AM, Schaffer T, Seibold-Schmid B, Muller S, Seibold F 2008 Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol. Motil. Aug 6 [Epub ahead of print].

• Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F 2008 Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm. Bowel Dis. 14: 32-39.

• Schroder O, Naumann M, Stein J 2004 Anti-Saccharomyces cerevisiae antibodies and response to infliximab in refractory Crohn's disease. Aliment. Pharmacol. Ther. 20: 823-824. *

• Seibold F, Boldt AB, Seibold-Schmid B, Schoepfer AM, Flogerzi B, Muller S, Kun JF 2007 Association of deficiency for mannan-binding lectin with anti-mannan antibodies in Crohn's disease: a family study. Inflamm. Bowel Dis. 13: 1077-1082. *

• Seibold F, Boldt AB, Seibold-Schmid B, Schoepfer AM, Flogerzi B, Muller S, Kun JF 2007 Deficiency for mannan-binding lectin is associated with antibodies to Saccharomyces cerevisiae in patients with Crohn’s disease and their relatives. Gut 56: 152. *

• Seibold F, Konrad A, Flogerzi B, Seibold-Schmid B, Arni S, Juliger S, Kun JF 2004 Genetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn's disease. Gastroenterology 127: 1076-1084. *

• Seibold F, Stich O, Hufnagl R, Kamil S, Scheurlen M 2001 Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand. J. Gastroenterol. 36: 196-201. *

• Sendid B, Colombel JF, Jacquinot PM, Faille C, Fruit J, Cortot A, Lucidarme D, Camus D, Poulain D 1996 Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin. Diagn. Lab. Immunol. 3: 219-226. *

• Sendid B, Quinton JF, Charrier G, Goulet O, Cortot A, Grandbastien B, Poulain D, Colombel JF 1998 Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am. J. Gastroenterol. 93: 1306-1310. *

• Shafran I, Piromalli C, Decker JW, Sandoval J, Naser SA, El-Zaatari FA 2002 Seroreactivities against Saccharomyces cerevisiae and Mycobacterium avium subsp. paratuberculosis p35 and p36 antigens in Crohn's disease patients. Dig. Dis. Sci. 47: 2079-2081. *

• Shanahan F 2006 Probiotics: promise, problems, and progress. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 41-45. *

• Shinzaki S, Iijima H, Nakagawa T, Egawa S, Nakajima S, Ishii S, Irie T, Kakiuchi Y, Nishida T, Yasumaru M, Kanto T, Tsujii M, Tsuji S, Mizushima T, Yoshihara H, Kondo A, Miyoshi E, Hayashi N 2008 IgG oligosaccharide alterations are a novel diagnostic marker for disease activity and the clinical course of inflammatory bowel disease. Am. J. Gastroenterol. 103: 1173-1181. *

• Shoenfeld Y, Carp HJ, Molina V, Blank M, Cervera R, Balasch J, Tincani A, Faden D, Lojacono A, Doria A, Konova E, Meroni PL 2006 Autoantibodies and prediction of reproductive failure. Am. J. Reprod. Immunol. 56: 337-344.

• Simondi D, Mengozzi G, Betteto S, Bonardi R, Ghignone RP, Fagoonee S, Pellicano R, Sguazzini C, Pagni R, Rizzetto M, Astegiano M 2008 Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm. Bowel Dis. 14: 645-651.

• Smith BR, Arnott ID, Drummond HE, Nimmo ER, Satsangi J 2004 Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm. Bowel Dis. 10: 521-528. *

• Spivak J, Landers CJ, Vasiliauskas EA, Abreu MT, Dubinsky MC, Papadakis KA, Ippoliti A, Targan SR, Fleshner PR 2006 Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm. Bowel Dis. 12: 1122-1130. *

• Standaert-Vitse A, Jouault T, Vandewalle P, Mille C, Seddik M, Sendid B, Mallet JM, Colombel JF, Poulain D 2006 Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibodies markers of Crohn’s disease. Gastroenterology 130: 1764-1775. *

• Steele IL, Levy C, Lindor KD 2007 Primary sclerosing cholangitis - approach to diagnosis. MedGenMed. 9: 20.

• Surawicz CM 1998 Clostridium difficile disease: diagnosis and treatment. Gastroenterologist 6: 60-65.

• Surawicz CM 2004 Treatment of recurrent Clostridium difficile-associated disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 32-38. *

• Surawicz CM, McFarland LV 1999 Pseudomembranous colitis: causes and cures. Digestion 60: 91-100.

• Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J 2000 Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 46: 58-63. *

• Suzuki H, Fukuda Y, Koizuka H, Tomita T, Hori K, Suzuki M, O'Morain C 2008 Dietary antigens in Crohn's disease: antibodies to porcine pancreatic amylase. Am. J. Gastroenterol. 103: 656-664. *

• Targan SR 1999 The utility of ANCA and ASCA in inflammatory bowel disease. Inflamm. Bowel Dis. 5: 61-63. *

• Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM 2005 Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 128: 2020-2028. *

• Teml A, Kratzer V, Schneider B, Lochs H, Norman GL, Gangl A, Vogelsang H, Reinisch W 2003 Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am. J. Gastroenterol. 98: 2226-2231. *

• Teml A, Reinisch W 2004 Anti-Saccharomyces cerevisiae antibody and 5-aminosalicylic acid treatment: response. Am. J. Gastroenterol. 99: 956. *

• Teoh KL, Mackay IR, Rowley MJ, Fussey SP 1994 Enzyme inhibitory autoantibodies to pyruvate dehydrogenase complex in primary biliary cirrhosis differ for mammalian, yeast and bacterial enzymes: implications for molecular mimicry. Hepatology 19: 1029-1033.

• Torok HP, Glas J, Gruber R, Brumberger V, Strasser C, Kellner H, Marker-Hermann E, Folwaczny C 2004 Inflammatory bowel disease-specific autoantibodies in HLA-B27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA. Digestion 70: 49-54.

• Toumi D, Mankai A, Belhadj R, Ghedira-Besbes L, Jeddi M, Ghedira I 2007 Anti-Saccharomyces cerevisiae antibodies in coeliac disease. Scand. J. Gastroenterol. 42: 821-826. *

• Uzoegwu PN, Baum H, Williamson J 1984 Detection of an antigen to primary biliary cirrhosis in wild type and petite mutant Saccharomyces cerevisiae. Cell Biol. Int. Rep. 8: 987-992.

• van den Bogaerde J, Kamm MA, Knight SC 2001 Immune sensitization to food, yeast and bacteria in Crohn's disease. Aliment. Pharmacol. Ther. 15: 1647-1653. *

• Vandewalle-El Khoury P, Colombel JF, Joossens S, Standaert-Vitse A, Collot M, Halfvarson J, Ayadi A, Landers CJ, Vermeire S, Rutgeerts P, Targan SR, Chamaillard M, Mallet JM, Sendid B, Poulain D 2008 Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction. Am. J. Gastroenterol. 103: 949-957. *

• Vasiliauskas E 2003 Recent advances in the diagnosis and classification of inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 493-500.

• Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR 2000 Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 47: 487-496. *

• Vergara T, Cofre P, Cifuentes S, Pulgar U, Puebla C, Velasco S 2006 Presence of antineutrophil cytoplasmic antibodies (ANCA) and anti Saccharomyces cerevisiae antibodies (ASCA) among patients with ulcerative colitis. Rev. Med. Chil. 134: 960-964.

• Vermeire S, Peeters M, Vlietinck R, Joossens S, Den Hond E, Bulteel V, Bossuyt X, Geypens B, Rutgeerts P 2001 Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm. Bowel Dis. 7: 8-15. *

• Vernier G, Sendid B, Poulain D, Colombel JF 2004 Relevance of serologic studies in inflammatory bowel disease. Curr. Gastroenterol. Rep. 6: 482-487.

• Villarruel G, Rubio DM, Lopez F, Cintioni J, Gurevech R, Romero G, Vandenplas Y 2007 Saccharomyces boulardii in acute childhood diarrhoea: a randomized, placebo-controlled study. Acta Paediatr. 96: 538-541. *

• Vind I, Jespersgaard C, Hougs L, Riis L, Dinesen L, Andersen PS, Locht H, Jess T, Munkholm P 2005 Genetic and environmental factors in monozygotic twins with Crohn's disease and their first-degree relatives: a case report. Digestion 71: 262-265.

• Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J 2004 Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin. Exp. Immunol. 135: 490-496. *

• Wen Z, Fiocchi C 2004 Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin. Dev. Immunol. 11: 195-204. *

• Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, Munkholm P, Langholz E, Bodini P, O'morain C, Katsanos K, Tsianos E, Vermeire S, Van Zeijl G, Limonard C, Hoie O, Vatn M, Moum B, et al 2006 Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand. J. Gastroenterol. Suppl. 243: 46-54. *

• Wong SL, Zhang LV, Tong AH, Li Z, Goldberg DS, King OD, Lesage G, Vidal M, Andrews B, Bussey H, Boone C, Roth FP 2004 Combining biological networks to predict genetic interactions. Proc. Natl. Acad. Sci. U.S.A. 101: 15682-15687. *

• Wu X, Lu XH 2006 The phenotype and clinical patterns of Crohn's disease in the Chinese. Zhonghua Nei Ke Za Zhi 45: 661-663.

• Yacyshyn BR, Schievella A, Sewell KL, Tami JA 2005 Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1*. Clin. Exp. Immunol. 141: 141-147. *

• Young Y, Abreu MT 2006 Advances in the pathogenesis of inflammatory bowel disease. Curr. Gastroenterol. Rep. 8: 470-477.

• Zheng JJ 2006 Clinical aspects of ulcerative colitis in mainland China. Chin. J. Dig. Dis. 7: 71-75.

• Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A 2004 Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am. J. Gastroenterol. 99: 2235-2241. *

Number of references = 236

www psc-literature.org